Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
journalStr:"WHO International Clinical Trials Registry Platform"
format_facet:"Aufsätze"
topic_facet:"Recruitment Status: Authorised-recruitment may be ongoing or finished"
topic_facet:"Medical Condition: Relapsed/Refractory Multiple Myeloma MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Relapsed%2FRefractory+Multiple+Myeloma+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
/vufind/Search/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Relapsed%2FRefractory+Multiple+Myeloma+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
Search /vufind/Search2/Results?filter%5B%5D=journalStr%3A%22WHO+International+Clinical+Trials+Registry+Platform%22&filter%5B%5D=format_facet%3A%22Aufs%C3%A4tze%22&filter%5B%5D=topic_facet%3A%22Recruitment+Status%3A+Authorised-recruitment+may+be+ongoing+or+finished%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Relapsed%2FRefractory+Multiple+Myeloma+MedDRA+version%3A+21.0Level%3A+LLTClassification+code+10028228Term%3A+Multiple+myelomaSystem+Organ+Class%3A+100000004864%3BTherapeutic+area%3A+Diseases+%5BC%5D+-+Cancer+%5BC04%5D%22&lookfor=Dexamethasone+OR+corticosteroid&type=AllFields
PubPharm (40)
1
Phase III study of belantamab mafodotin, bortezomib, and dexamethasone (B-Vd) versus daratumumab, bortezomib, and dexamethasone (D-Vd) in participants with relapsed/refractory multiple myeloma : DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
Phase III study of belantamab mafodotin, bortezomib, and dexamethasone (B-Vd) versus daratumumab, bortezomib, and dexamethasone (D-Vd) in participants with relapsed/refractory multiple myeloma : DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared with the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants with Relapsed/Refractory Multiple Myeloma
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
3
A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multiple myeloma : A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
4
A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multiple myeloma : A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
5
A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multiple myeloma : A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
6
A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multiple myeloma : A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
7
A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multiple myeloma : A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
8
A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multiple myeloma : A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
9
A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multiple myeloma : A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
10
A study of belantamab mafodotin compared to a combination of pomalidomide and dexamethasone in participants with relapsed/refractory multiple myeloma : A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide plus Low-dose Dexamethasone (pom/dex) in Participants with Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
enthalten in:
WHO International Clinical Trials Registry Platform
| 2022
Wird geladen...
1
2
3
4
Nächster »
[4]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Alle gewählten Filter entfernen
Filter aufheben
Zeitschrift: WHO International Clinical Trials Registry Platform
Filter aufheben
Medienart: Aufsätze
Filter aufheben
Thema: Recruitment Status: Authorised-recruitment may be ongoing or finished
Filter aufheben
Thema: Medical Condition: Relapsed/Refractory Multiple Myeloma MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
Medienart
Aufsätze
40
E-Artikel
40
E-Ressourcen
Zeitschriftentitel
WHO International Clinical Trials Registry Plat...
Thema
40
610
Medical Condition: Relapsed/Refractory Multiple...
40
Phase: Phase 3
Recruitment Status: Authorised-recruitment may ...
40
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
2
2023
10
2022
14
2021
14
2020
Erscheinungsjahr(e)
Von:
Bis:
Sprache
40
Englisch
Haven't found what you're looking for?
Wird geladen...